UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Risk prediction is improved by adding markers of subclinical organ damage to SCORE

European heart journal, 2010-04, Vol.31 (7), p.883-891

2010

Volltextzugriff (PDF)

Prognostic significance of left ventricular mass change during treatment of hypertension

JAMA : the journal of the American Medical Association, 2004-11, Vol.292 (19), p.2350

2004

Volltextzugriff (PDF)

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

Journal of the American College of Cardiology, 2005-03, Vol.45 (5), p.712-719

2005

Volltextzugriff (PDF)

[OP.4A.09] THE RELATIONSHIP OF ALL-CAUSE MORTALITY TO AVERAGE ON-TREATMENT SYSTOLIC BP IS RELATED TO BASELINE SYSTOLIC BP: IMPLICATIONS FOR INTERPRETATION OF THE SPRINT STUDY

Journal of hypertension, 2017-09, Vol.35 Suppl 2 - ESH 2017 Abstract Book (Supplement 2), p.e36-e36

2017

Volltextzugriff (PDF)

[OP.7B.06] RELATIONSHIP OF INCIDENT ATRIAL FIBRILLATION TO THE ELECTROCARDIOGRAPHIC STRAIN PATTERN IN HYPERTENSIVE PATIENTS WITH ELECTROCARDIOGRAPHIC LEFT VENTRICULAR HYPERTROPHY

Journal of hypertension, 2017-09, Vol.35 Suppl 2 - ESH 2017 Abstract Book (Supplement 2), p.e68-e68

2017

Volltextzugriff (PDF)

Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial

Circulation (New York, N.Y.), 2004-09, Vol.110 (11), p.1456-1462

2004

Volltextzugriff (PDF)

Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study

Hypertension (Dallas, Tex. 1979), 2005-02, Vol.45 (2), p.198-202

2005

Volltextzugriff (PDF)

Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation : The losartan intervention for end point reduction in hypertension (LIFE) study

Journal of the American College of Cardiology, 2005-03, Vol.45 (5), p.705-711

2005

Volltextzugriff (PDF)

Does Albuminuria Predict Cardiovascular Outcomes on Treatment With Losartan Versus Atenolol in Patients With Diabetes, Hypertension, and Left Ventricular Hypertrophy?: The LIFE study

Diabetes care, 2006-03, Vol.29 (3), p.595-600

2006

Volltextzugriff (PDF)

Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE Study

Journal of hypertension, 2006-04, Vol.24 (4), p.775-781

2006

Volltextzugriff (PDF)

Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy

Journal of hypertension, 2004-09, Vol.22 (9), p.1805-1811

2004

Volltextzugriff (PDF)

Impact of overweight and obesity on cardiac benefit of antihypertensive treatment

Nutrition, metabolism, and cardiovascular diseases, 2013-02, Vol.23 (2), p.122-129

2013

Volltextzugriff (PDF)

A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers

European journal of preventive cardiology, 2014-04, Vol.21 (4), p.434-441

2014

Volltextzugriff (PDF)

Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients

Circulation (New York, N.Y.), 2020-08, Vol.142 (7), p.621-642

2020

Volltextzugriff (PDF)

Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study

Hypertension (Dallas, Tex. 1979), 2005-01, Vol.45 (1), p.46-52

2005

Volltextzugriff (PDF)

Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study

Journal of hypertension, 2001-10, Vol.19 (10), p.1883-1891

2001

Volltextzugriff (PDF)

Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension

Journal of hypertension, 2021-08, Vol.39 (8), p.1522-1545

2021

Volltextzugriff (PDF)

Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: The LIFE study

Journal of human hypertension, 2011-03, Vol.25 (3), p.178-185

2011

Volltextzugriff (PDF)

Interleukin 6 in asymptomatic patients with nonsevere aortic valve stenosis: a post-hoc study of the SEAS trial

European heart journal, 2024-10, Vol.45 (Supplement_1)

2024

Volltextzugriff (PDF)

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study

Kidney international, 2004-11, Vol.66 (S92), p.S56-S58

2004

Volltextzugriff (PDF)

Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study

Journal of human hypertension, 2007-08, Vol.21 (8), p.625-632

2007

Volltextzugriff (PDF)

Incident atrial fibrillation and heart failure in treated hypertensive patients with left ventricular hypertrophy

European heart journal, 2022-10, Vol.43 (Supplement_2)

2022

Volltextzugriff (PDF)

Left atrial systolic force in hypertensive patients with left ventricular hypertrophy predicts atrial fibrillation

European heart journal, 2022-10, Vol.43 (Supplement_2)

2022

Volltextzugriff (PDF)

Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study

Nutrition, metabolism, and cardiovascular diseases, 2009-11, Vol.19 (9), p.634-640

2009

Volltextzugriff (PDF)

P826Increase in cardiac biomarkers during exercise stress test in patients with angiographically verified coronary artery disease

European heart journal, 2018-08, Vol.39 (suppl_1)

2018

Volltextzugriff (PDF)

1 – 25 von 256

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(242)
Mit Volltextzugriff
(242)

Publikationsform

Sprache

Englisch
(251)
Dänisch
(3)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(141)
Science & Technology
(140)
Life Sciences & Biomedicine
(139)
Male
(125)
Female
(124)
Cardiovascular System & Cardiology
(122)
Aged
(120)
Middle Aged
(118)
Hypertension
(100)
Biological And Medical Sciences
(90)
Medical Sciences
(90)
Peripheral Vascular Disease
(83)
Cardiology. Vascular System
(78)
Blood And Lymphatic Vessels
(71)
Hypertension - Drug Therapy
(69)
Arterial Hypertension. Arterial Hypotension
(67)
Hypertension - Complications
(60)
Risk Factors
(58)
Aged, 80 And Over
(57)
Losartan - Therapeutic Use
(57)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Risk prediction is improved by adding markers of subclinical organ damage to SCORE

Prognostic significance of left ventricular mass change during treatment of hypertension

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

[OP.4A.09] THE RELATIONSHIP OF ALL-CAUSE MORTALITY TO AVERAGE ON-TREATMENT SYSTOLIC BP IS RELATED TO BASELINE SYSTOLIC BP: IMPLICATIONS FOR INTERPRETATION OF THE SPRINT STUDY

[OP.7B.06] RELATIONSHIP OF INCIDENT ATRIAL FIBRILLATION TO THE ELECTROCARDIOGRAPHIC STRAIN PATTERN IN HYPERTENSIVE PATIENTS WITH ELECTROCARDIOGRAPHIC LEFT VENTRICULAR HYPERTROPHY

Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial

Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study

Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation : The losartan intervention for end point reduction in hypertension (LIFE) study

Does Albuminuria Predict Cardiovascular Outcomes on Treatment With Losartan Versus Atenolol in Patients With Diabetes, Hypertension, and Left Ventricular Hypertrophy?: The LIFE study

Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE Study

Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy

Impact of overweight and obesity on cardiac benefit of antihypertensive treatment

A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers

Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients

Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study

Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study

Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension

Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: The LIFE study

Interleukin 6 in asymptomatic patients with nonsevere aortic valve stenosis: a post-hoc study of the SEAS trial

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study

Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study

Incident atrial fibrillation and heart failure in treated hypertensive patients with left ventricular hypertrophy

Left atrial systolic force in hypertensive patients with left ventricular hypertrophy predicts atrial fibrillation

Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study

P826Increase in cardiac biomarkers during exercise stress test in patients with angiographically verified coronary artery disease

Suchergebnisse filtern